Joseph Cappello - Jan 25, 2023 Form 3 Insider Report for GENELUX CORP (GNLX)

Role
VP, Pharmaceutical Development
Signature
/s/ Sean Ryder, J.D., Attorney-in-Fact
Stock symbol
GNLX
Transactions as of
Jan 25, 2023
Transactions value $
$0
Form type
3
Date filed
1/25/2023, 06:24 PM
Next filing
May 2, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding GNLX Stock Option (right to buy) Jan 25, 2023 Common Stock 50K $9.00 Direct F1
holding GNLX Stock Option (right to buy) Jan 25, 2023 Common Stock 16.7K $9.00 Direct F1
holding GNLX Stock Option (right to buy) Jan 25, 2023 Common Stock 80K $10.50 Direct F1
holding GNLX Stock Option (right to buy) Jan 25, 2023 Common Stock 13.3K $10.50 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Immediately exercisable.
F2 25% of the shares shall vest on September 24, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter.